Name | AZD0424 |
---|
Description | AZD0424 is an orally active, and dual selective Src/Abl kinase inhibitor with potential antineoplastic activity[1]. AZD0424 induces apoptosis and cell cycle arrest in lymphoma cells[2]. |
---|---|
Related Catalog | |
Target |
Src/Abl kinase inhibitor (SrcK-I), apoptosis[1] |
In Vitro | AZD0424 (1-5 μM; 24-48 hours) is emerged to be the more effective of the three tested inhibitors (AZM559756, AZD0530 and AZD0424), inducing the highest levels of apoptosis with the lowest concentrations in lymphoma cells[2]. AZD0424 (5 μM; 48 hours) leads to increased G0/G1 cell cycle arrest in DOHH-2 and WSU-NHL cells, whereas the cell cycle progression of the nonsensitive cell lines Raji and Jurkat remains unaffected[2]. Apoptosis Analysis[2] Cell Line: DOHH-2, WSU-NHL, Raji, Jurkat, Karpas-299 and HUT78 cells Concentration: 1 μM; 2 μM; 3 μM; 4 μM; 5 μM; Incubation Time: 24 hours, 48 hours Result: Induced apoptosis in lymphoma cells. Cell Cycle Analysis[2] Cell Line: DOHH-2, WSU-NHL, Raji and Jurkat cells Concentration: 1 μM; 2 μM; 3 μM; 4 μM; 5 μM; Incubation Time: 48 hours Result: Increased G0/G1 cell cycle arrest in DOHH-2 and WSU-NHL cells. |
References |
Molecular Formula | C25H29ClN6O5 |
---|---|
Molecular Weight | 528.99 |